Swiss drug major Roche Holding AG (RHHBY) reported that its net income attributable to shareholders for the first half of 2025 rose to 7.410 billion Swiss francs or 9.23 francs per share from last year's 6.258 billion francs or 7.80 francs per share, driven by the strong operating performance and lower impairment charges related to intangible assets.
Core earnings per share were 11.08 francs compared to 10.23 francs last year.
Core operating profit increased by 6% in CHF to 12.0 billion francs, driven by higher sales and effective cost management.
The appreciation of the Swiss franc against most currencies, notably the US dollar, had an adverse impact on the results when reported in Swiss francs compared to constant exchange rates.
Revenue for the period grew to 31.849 billion francs from 30.756 billion francs last year, due to strong demand for pharmaceutical products.
The company confirmed its outlook for fiscal year 2025. It still expects an increase in group sales in the mid single digit range (CER). Core earnings per share are targeted to develop in the high single digit range (CER). It expects to further increase its dividend in Swiss francs.
For more earnings news, earnings calendar, and earnings for stocks, visit rttnews.com.
For comments and feedback contact: editorial@rttnews.com
Business News
April 17, 2026 15:29 ET The ongoing conflict in the Middle East continues to raise concerns for policymakers who worry about the impact of the supply shock and high energy prices on the real economy. Producer price data and various survey results on the housing market were the main news from the U.S. this week. In Europe, industrial production data for the euro area gained attention. GDP figures out of China and the policy move by the Singapore central bank were in focus in Asia.